ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
7.74
-0.20 (-2.52%)
Apr 29, 2026, 2:21 PM EDT - Market open
ARS Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Cash & Equivalents | 41.32 | 50.82 | 70.97 | 210.52 | 60.06 | Upgrade
|
| Short-Term Investments | 203.67 | 263.21 | 157.39 | 63.86 | - | Upgrade
|
| Cash & Short-Term Investments | 244.99 | 314.02 | 228.36 | 274.38 | 60.06 | Upgrade
|
| Cash Growth | -21.98% | 37.51% | -16.77% | 356.82% | 144.94% | Upgrade
|
| Accounts Receivable | 25.35 | 8.18 | - | - | - | Upgrade
|
| Other Receivables | 1 | 1 | 0.69 | 1.01 | 0 | Upgrade
|
| Receivables | 26.35 | 9.18 | 0.69 | 1.01 | 0 | Upgrade
|
| Inventory | 8.37 | 5.21 | - | - | - | Upgrade
|
| Prepaid Expenses | 5.19 | 5.89 | 2.03 | 2.31 | 0.67 | Upgrade
|
| Other Current Assets | - | - | 0.65 | - | - | Upgrade
|
| Total Current Assets | 284.9 | 334.3 | 231.73 | 277.7 | 60.73 | Upgrade
|
| Property, Plant & Equipment | 2.47 | 1.07 | 0.82 | 0.77 | 0.69 | Upgrade
|
| Other Intangible Assets | 14.45 | 7.37 | 0.62 | - | - | Upgrade
|
| Other Long-Term Assets | 25.84 | 8.42 | 0.02 | 2.96 | 0.02 | Upgrade
|
| Total Assets | 327.65 | 351.15 | 233.19 | 281.44 | 61.45 | Upgrade
|
| Accounts Payable | 9.16 | 14.13 | 0.76 | 1.66 | 1.79 | Upgrade
|
| Accrued Expenses | 10.05 | 2.47 | 0.36 | 2.1 | 1.3 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | - | - | 3.48 | Upgrade
|
| Current Portion of Leases | - | - | 0.24 | 0.23 | 0.14 | Upgrade
|
| Current Income Taxes Payable | - | - | - | 0.17 | - | Upgrade
|
| Current Unearned Revenue | 0.61 | 0.56 | - | 0.28 | 1.46 | Upgrade
|
| Other Current Liabilities | 19.33 | 6.29 | 1.04 | 1 | 0.02 | Upgrade
|
| Total Current Liabilities | 39.15 | 23.44 | 2.39 | 5.44 | 8.19 | Upgrade
|
| Long-Term Debt | 168.51 | 69.38 | - | - | 4.93 | Upgrade
|
| Long-Term Leases | - | - | 0.04 | 0.25 | 0.48 | Upgrade
|
| Long-Term Unearned Revenue | 1.13 | 1.53 | - | 2.85 | 3 | Upgrade
|
| Other Long-Term Liabilities | 4.61 | - | - | - | 0.08 | Upgrade
|
| Total Liabilities | 213.39 | 94.36 | 2.43 | 8.55 | 16.68 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0 | Upgrade
|
| Additional Paid-In Capital | 408.73 | 379.87 | 362 | 349.41 | 10.98 | Upgrade
|
| Retained Earnings | -294.6 | -123.31 | -131.3 | -76.94 | -42.26 | Upgrade
|
| Comprehensive Income & Other | 0.13 | 0.22 | 0.05 | 0.41 | - | Upgrade
|
| Total Common Equity | 114.26 | 256.8 | 230.76 | 272.89 | -31.27 | Upgrade
|
| Shareholders' Equity | 114.26 | 256.8 | 230.76 | 272.89 | 44.77 | Upgrade
|
| Total Liabilities & Equity | 327.65 | 351.15 | 233.19 | 281.44 | 61.45 | Upgrade
|
| Total Debt | 168.51 | 69.38 | 0.27 | 0.48 | 9.03 | Upgrade
|
| Net Cash (Debt) | 76.47 | 244.64 | 228.09 | 273.9 | 51.03 | Upgrade
|
| Net Cash Growth | -68.74% | 7.26% | -16.73% | 436.74% | 251.86% | Upgrade
|
| Net Cash Per Share | 0.78 | 2.39 | 2.40 | 6.86 | 1.77 | Upgrade
|
| Filing Date Shares Outstanding | 99.3 | 98.12 | 96.5 | 94.4 | 25.7 | Upgrade
|
| Total Common Shares Outstanding | 99.29 | 97.95 | 96.41 | 93.94 | 25.7 | Upgrade
|
| Working Capital | 245.75 | 310.86 | 229.34 | 272.26 | 52.54 | Upgrade
|
| Book Value Per Share | 1.15 | 2.62 | 2.39 | 2.90 | -1.22 | Upgrade
|
| Tangible Book Value | 99.81 | 249.43 | 230.14 | 272.89 | -31.27 | Upgrade
|
| Tangible Book Value Per Share | 1.01 | 2.55 | 2.39 | 2.90 | -1.22 | Upgrade
|
| Machinery | - | - | 0.67 | 0.38 | 0.09 | Upgrade
|
| Leasehold Improvements | - | - | 0.02 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.